MedChunk
Medically reviewed

Alzheimer's Disease Treatment: Options and What to Expect

Explore Alzheimer's disease treatment options, including memory medicines, newer therapies, supportive care, side effects, and what families can expect.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 26, 2023 13 min read

Alzheimer's disease treatment can help manage memory problems, support daily activities, and, in some people with early Alzheimer's, slow how quickly the disease gets worse. Treatment may include medicines, newer therapies that target changes in the brain, and practical support at home. There is no cure yet, but a personalized care plan can help people stay comfortable, active, and independent for as long as possible.

What Are the Main Treatments for Alzheimer's Disease?

Alzheimer's disease affects memory, thinking, communication, and the ability to manage everyday tasks. Treatment focuses on maintaining these abilities where possible, managing symptoms, and supporting quality of life.

There are two main types of Alzheimer's medicines. Some help manage symptoms by supporting communication between nerve cells. Others target amyloid, a protein that builds up in the brain, and may slow disease progression in selected people with early Alzheimer's.

According to the NHS, medicines can temporarily improve certain symptoms, while non-medication approaches can help people and families manage daily challenges.

Healthcare professionals choose treatments based on the person's diagnosis, current abilities, other medical conditions, medications, and care goals. A neurologist, memory specialist, or another clinician experienced in dementia care may help develop the treatment plan.

Medicines That Help With Memory and Thinking

Several established medicines are used to manage cognitive symptoms, such as problems with memory, attention, and thinking. These treatments do not stop Alzheimer's disease, but they may help some people maintain their abilities for a period of time.

Cholinesterase inhibitors: Donepezil, rivastigmine, and galantamine

Cholinesterase inhibitors increase the availability of acetylcholine, a chemical that helps nerve cells communicate. Alzheimer's disease affects this communication, which contributes to difficulties with memory and other mental abilities.

Commonly prescribed medicines include:

  • Donepezil: Used to manage symptoms of Alzheimer's dementia, including in later stages.
  • Rivastigmine: Available in oral forms and as a skin patch, which may be helpful for some people who have difficulty taking tablets.
  • Galantamine: Generally used for mild-to-moderate Alzheimer's dementia.

These medicines may help stabilize or modestly improve memory, attention, or daily functioning for some people. However, noticeable improvement is not guaranteed, and their benefits can become less apparent as Alzheimer's progresses.

Possible side effects include nausea, vomiting, diarrhea, reduced appetite, and weight loss. Some people tolerate one medicine better than another. A clinician may adjust the dose or consider a different option if side effects are troublesome.

Memantine for moderate-to-severe Alzheimer's

Memantine works differently from cholinesterase inhibitors. It regulates the effects of glutamate, a chemical involved in communication between nerve cells.

It is commonly prescribed for moderate-to-severe Alzheimer's disease and may help some people maintain certain daily activities or thinking abilities for longer. It may also be used when cholinesterase inhibitors are unsuitable or alongside one of those medicines.

Potential side effects include dizziness, headache, constipation, and confusion. Healthcare professionals consider kidney function and other health factors when prescribing memantine.

The Alzheimer's Association describes these symptom-managing medicines as treatments that may reduce or stabilize certain difficulties without reversing the underlying brain damage.

Can New Alzheimer's Treatments Slow the Disease?

Newer disease-modifying therapies represent an important development in Alzheimer's treatment. Unlike medicines that mainly address symptoms, these treatments target biological changes associated with the disease.

Two such treatments are lecanemab and donanemab. Both are anti-amyloid antibody therapies designed to reduce amyloid deposits in the brain.

These treatments are intended for selected people with early symptomatic Alzheimer's disease, including mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia. They are not established treatments for advanced disease.

Lecanemab (Leqembi)

Lecanemab targets beta-amyloid, a protein that forms abnormal deposits in the brains of people with Alzheimer's disease.

Clinical trials found that it slowed cognitive and functional decline in people with early symptomatic Alzheimer's compared with placebo. This means that some people receiving treatment experienced a slower worsening of their abilities, rather than a recovery of previously lost memory.

The Alzheimer's Association explains that lecanemab has received U.S. Food and Drug Administration approval for early Alzheimer's disease with confirmed amyloid buildup. In the United States, treatment options include intravenous infusions and approved under-the-skin injection regimens.

Its use requires assessment by an experienced healthcare team, and access may differ between countries and healthcare systems.

Donanemab (Kisunla)

Donanemab is another antibody treatment that targets amyloid deposits in the brain. It has demonstrated an ability to slow cognitive and functional decline in some people with early symptomatic Alzheimer's disease.

Donanemab is administered through intravenous infusions, generally every four weeks. The duration of treatment depends on clinical decisions and how the person's amyloid levels respond.

According to the Alzheimer's Association, donanemab is approved in the United States for early Alzheimer's disease in people with confirmed amyloid plaques. It is not a cure and has not been shown to restore memory that has already been lost.

Who may qualify for anti-amyloid treatment?

Before considering these medicines, a specialist generally needs to establish that the person has early symptomatic Alzheimer's and confirm amyloid pathology through appropriate testing.

Assessment may include:

  • A review of memory, thinking, and daily functioning.
  • Tests to confirm amyloid buildup, such as amyloid PET imaging or cerebrospinal fluid testing.
  • Brain MRI scans to evaluate treatment-related risks.
  • A review of medical history, current medications, and possible bleeding risks.
  • A discussion of expected benefits, risks, monitoring requirements, treatment access, and costs.

Not everyone with early Alzheimer's is an appropriate candidate. Treatment availability, regulatory approval, and insurance coverage also vary by location.

What Are the Risks of New Alzheimer's Medicines?

Anti-amyloid treatments can cause amyloid-related imaging abnormalities, commonly called ARIA. These changes may involve swelling or small areas of bleeding in the brain.

ARIA may not cause noticeable symptoms and may be found during routine MRI monitoring. In other cases, symptoms may occur, and rarely, complications can be serious or life-threatening.

Possible warning signs include:

  • New or worsening headache
  • Unusual confusion
  • Dizziness or changes in vision
  • Difficulty walking or maintaining balance
  • Seizures

Anyone receiving anti-amyloid treatment who develops new neurological symptoms should seek urgent medical assessment. Sudden weakness, seizures, or a severe headache require emergency evaluation.

Regular MRI scans are part of treatment monitoring. A specialist may also discuss genetic factors, including APOE-related risk, and review medicines that affect bleeding before starting therapy.

How Can Alzheimer's Be Managed Without Medication?

Medicines are only one part of Alzheimer's care. Practical support, structured activities, and changes to the home environment can make daily life more manageable.

Cognitive stimulation and meaningful activities

Cognitive stimulation therapy involves structured activities that encourage thinking, communication, and social interaction. It may be offered to people with mild-to-moderate dementia.

Activities may include discussing familiar subjects, playing suitable games, listening to music, looking at photographs, and taking part in group sessions.

The aim is not to cure memory loss but to encourage engagement and support well-being.

Daily routines and home adjustments

Predictable routines can reduce uncertainty and make familiar tasks easier to follow. Families may find it helpful to maintain regular times for meals, activities, rest, and medication.

Useful adjustments include:

  • Keeping frequently used objects in consistent places.
  • Using calendars, clocks, and simple written reminders.
  • Reducing unnecessary noise and distractions.
  • Improving lighting and removing household trip hazards.
  • Providing assistance with complicated tasks while preserving independence where safe.

Occupational therapists and dementia care professionals can recommend changes based on the person's abilities and home environment.

Physical activity, sleep, and social connection

Suitable physical activity, regular sleep routines, and opportunities for social interaction are valuable parts of supportive care.

Walking, gentle exercise, and enjoyable activities may support physical health, mood, and everyday well-being. The type and intensity of activity should reflect the person's mobility, general health, and safety needs.

Although these approaches support overall health, they should not be presented as proven cures or substitutes for indicated medical treatment.

How Are Agitation, Anxiety, and Sleep Problems Treated?

Some people with Alzheimer's experience agitation, anxiety, sleep disturbances, or changes in behavior. These difficulties can affect both the person and those providing care.

Treatment usually begins by looking for possible contributing factors, including pain, illness, medication effects, disrupted routines, or environmental discomfort.

Non-drug approaches are often considered first. These may include calm communication, reassurance, suitable activities, consistent routines, and reducing upsetting environmental triggers.

The NHS notes that medicines may sometimes be considered for significant behavioral or psychological symptoms, but antipsychotic drugs carry serious risks and should be used cautiously when clinically necessary.

When medication is needed for severe distress or behavior that creates a risk of harm, a healthcare professional should assess the possible benefits and harms. Antipsychotics are associated with increased risks, including stroke and death, in older people with dementia.

Sleep problems may also require review of daily activities, environmental factors, existing medicines, and other health conditions before additional medication is considered.

What Should Families Expect After Treatment Starts?

Alzheimer's treatment usually involves ongoing assessment rather than a single prescription or procedure. Healthcare professionals review how well a treatment is tolerated and whether it is meeting the person's care goals.

During the first weeks and months

When symptom-managing medicines are started, clinicians may begin with a lower dose and increase it gradually if appropriate. Follow-up visits help identify side effects and assess any changes in daily functioning.

Some people appear more attentive or better able to participate in activities. Others may remain relatively stable for a period without an obvious improvement. The absence of dramatic changes does not automatically mean the treatment has no benefit.

For anti-amyloid therapies, the process is different. Treatment involves specialized assessments, scheduled administration, and MRI monitoring. The expected benefit is a slower rate of decline over time, not immediate symptom relief.

As Alzheimer's progresses

Alzheimer's is a progressive condition, so care needs often change over time. A treatment that was helpful earlier may need reassessment as the person's abilities and health change.

Some people eventually need more assistance with dressing, eating, mobility, or communication. Medication reviews, caregiver support, rehabilitation services, and changes to the living environment can help address evolving needs.

In more advanced stages, care often places greater emphasis on comfort, nutrition, safe movement, symptom relief, and support with daily activities. Palliative care may be useful for addressing distressing symptoms and helping families make care decisions.

How Do Doctors Decide Which Treatment Is Best?

There is no single Alzheimer's treatment plan that suits everyone. Decisions are made through discussion between the person, their healthcare team, and, when appropriate, family members or caregivers.

Important considerations include the stage of Alzheimer's disease, existing medical conditions, potential side effects, the person's preferences, and the practical demands of treatment.

Useful questions for a treatment appointment include:

  • What is the main goal of the recommended treatment?
  • How will we know whether it is helping?
  • Which side effects should we watch for?
  • Would additional testing help determine eligibility for newer treatments?
  • How often will follow-up visits or scans be needed?
  • What support services are available for family members and caregivers?

It is also important to tell the healthcare team about all prescription medicines, over-the-counter products, and supplements being used. Products advertised as natural memory cures should be discussed with a clinician because their effectiveness and safety may not be established.

Can Alzheimer's Disease Treatment Improve Quality of Life?

Yes. Although treatment cannot currently cure Alzheimer's, an appropriate combination of medication, supportive therapies, and practical assistance can help people maintain meaningful activities and manage symptoms.

The most useful outcomes are not always measured by memory test scores alone. Being able to participate in conversations, enjoy familiar activities, remain comfortable, and receive appropriate assistance may be equally important.

Regular review with a dementia care team helps ensure that treatment remains appropriate as needs change. Early discussion of care goals also gives individuals and families more opportunity to make informed decisions together.

Frequently Asked Questions

Common questions about Alzheimer's medicines, newer treatments, and ongoing care.

What is the most effective treatment for Alzheimer's disease?

There is no single best treatment for everyone. Donepezil, rivastigmine, galantamine, and memantine may help manage certain symptoms. For selected people with early Alzheimer's, anti-amyloid treatments such as lecanemab or donanemab may slow disease progression. A specialist can help determine which approach is appropriate.

Can Alzheimer's medication bring back lost memories?

Current treatments cannot reliably restore memories or reverse brain damage caused by Alzheimer's disease. Some symptom-managing medicines may temporarily improve or stabilize certain cognitive abilities, while disease-modifying treatments may slow further decline in eligible people.

How long does Alzheimer's medication take to work?

The timeline depends on the medicine and its purpose. Symptom-managing drugs are usually assessed over weeks to months, including time for dose adjustments. Anti-amyloid treatments are evaluated over longer periods because their goal is to slow decline rather than produce immediate improvement.

Are lecanemab and donanemab suitable for advanced Alzheimer's?

These treatments were studied in people with early symptomatic Alzheimer's disease, including mild cognitive impairment due to Alzheimer's and mild Alzheimer's dementia. Their safety and effectiveness when started in more advanced Alzheimer's have not been established. Eligibility requires specialist assessment.

Should Alzheimer's medicine be stopped when symptoms get worse?

Not necessarily. Alzheimer's can progress even while a medicine is providing some benefit. A healthcare professional should review symptoms, side effects, daily functioning, and treatment goals before deciding whether to continue, adjust, or stop medication. Medicines should not be discontinued without discussing the decision with the prescribing clinician.

Citations

  1. NHS – Alzheimer's Disease: Treatment
  2. Alzheimer's Association – Medications for Memory, Cognition and Dementia-Related Behaviors
  3. Alzheimer's Association – Lecanemab Approved for Treatment of Early Alzheimer's Disease
  4. Alzheimer's Association – Donanemab Approved for Treatment of Early Alzheimer's Disease
Share this article